Compare DARE & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DARE | MDXH |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2M | 21.1M |
| IPO Year | 2014 | 2021 |
| Metric | DARE | MDXH |
|---|---|---|
| Price | $0.93 | $0.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $10.00 | $7.67 |
| AVG Volume (30 Days) | 188.5K | ★ 228.8K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,807,885.00 | N/A |
| Revenue This Year | $2,115.12 | $30.78 |
| Revenue Next Year | $122.62 | $18.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.13 | $0.40 |
| 52 Week High | $3.78 | $5.33 |
| Indicator | DARE | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 25.74 | 82.56 |
| Support Level | N/A | $0.68 |
| Resistance Level | $2.14 | $2.23 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 16.31 | 62.47 |
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.